Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00643929 · ClinicalTrials.gov registry record
LENS - Long-term Eltrombopag Observational Study
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 164
- Enrollment target
NCT00643929: Completed study, sponsored by GlaxoSmithKline.
NCT00643929 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 164 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00643929 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 164 participants
- Enrollment target
Study Summary
A long term observational ocular safety study in adults who have received study medication (either active drug or placebo) in a phase II or III clinical study evaluating eltrombopag. The study will follow subjects for 2.5 years following their last ocular assessment on their prior treatment study (regardless of the therapeutic indication) and will describe long-term ocular safety with respect to changes in the lenses over time from all subjects.
Interventions
- DRUG Eltrombopag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2007-02 |
| Est. Completion | 2013-03 |
What the finished NCT00643929 record still lists
NCT00643929 is an observational study that tracks outcomes without assigning an intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Eltrombopag is the first listed.
NCT00643929 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00643929 about?
NCT00643929 is a clinical study titled "LENS - Long-term Eltrombopag Observational Study". A long term observational ocular safety study in adults who have received study medication (either active drug or placebo) in a phase II or III clinical study evaluating eltrombopag. The study will follow subjects for 2.5 years following their last ocular assessment on their prior treatment study (r...
What is the current status of trial NCT00643929?
This trial is currently completed. The enrollment target is 164 participants. The study started on 2007-02. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00643929?
The interventions under investigation include: Eltrombopag (DRUG).
Who is sponsoring clinical trial NCT00643929?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia